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Abstract Aims/hypothesis: The acute-phase proteins,
serum amyloid As (SAA), are precursors of amyloid A,
involved in the pathogenesis of AA amyloidosis. This work
started with the characterisation of systemic AA amyloid-
osis concurrent with SAA overexpression in the subcuta-
neous white adipose tissue (sWAT) of an obese patient with
a leptin receptor deficiency. In the present study a series of
histopathological, cellular and gene expression studies was
performed to assess the importance of SAA in common
obesity and its possible production by mature adipocytes.
Materials and methods: Gene expression profiling was
performed in the sWAT of two extremely obese patients
with a leptin receptor deficiency. Levels of the mRNAs of
the different SAA isoforms were quantified in sWAT cel-
lular fractions from lean subjects and from obese subjects
before and after a very-low-calorie diet. These values were
subsequently compared with serum levels of SAA in these
individuals. In addition, histopathological analyses of sWAT
were performed in lean and obese subjects. Results: In
sWAT, the expression of SAA is more than 20-fold higher
in mature adipocytes than in the cells of the stroma vascular
fraction (p<0.01). Levels of SAA mRNA expression and
circulating levels of the protein are sixfold (p<0.001) and
3.5-fold (p<0.01) higher in obese subjects than in lean
subjects, respectively. In lean subjects, 5% of adipocytes
are immunoreactive for SAA, whereas the corresponding
value is greater than 20% in obese subjects. Caloric restric-
tion results in decreases of 45–75% in levels of the tran-
scripts for the SAA isoforms and in circulating levels of the
protein. Conclusions/interpretation: The results of the pres-
ent study indicate that SAA is expressed by sWAT, and its
production at this site is regulated by nutritional status. If
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amyloidosis is seen in the context of obesity, it is possible
that production of SAA by adipocytes could be a con-
tributory factor.
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Introduction
Obesity is associated with increased circulating levels of
inflammatory markers such as acute-phase proteins and
cytokines [1–5]. Increasing evidence suggests that cyto-
kines released from adipose tissue contribute to the de-
velopment of complications related to obesity, including
metabolic [6, 7] and cardiovascular diseases [8, 9]. Indeed,
adipose cells have been shown to secrete a wide number of
proinflammatory cytokines (i.e. TNF-α, TGF-β, interferon
γ and interleukins) and chemokines (macrophage inflam-
matory protein-1α, monocyte chemotactic protein-1) [10–
13]. It was recently shown that macrophage infiltration is
increased in the adipose tissue of obese rodents and rep-
resents an important source of inflammation in this tissue
[14, 15]. Like atherosclerosis [16], obesity may be viewed
as a metabolic as well as an inflammatory disease.
At present there is no clinical evidence of a direct re-
lationship between obesity and inflammation-related dis-
eases in humans. It is not known whether the production of
inflammatory mediators by adipose tissue in extreme forms
of adiposity may increase susceptibility to specific patho-
genic processes [17]. Gene expression profiling of human
genetic forms of obesity characterised by extreme adiposity
may help to identify the consequences of early-onset fat
mass accumulation on adipose tissue gene expression and
the development of inflammation-related complications.
We have previously reported the clinical and biological
features associated with extreme obesity due to a leptin
receptor (LEPR) deficiency [18]. Since the identification
of the mutation, the two sisters who participated in this
study have been under regular clinical care, and adipose
tissue studies were continued in order to gain further in-
sight into this very severe clinical situation that was ob-
served to progressively deteriorate.
More recently, we showed that the expression of key
transcription factors involved in adipose tissue differenti-
ation was normal in these two subjects [19]. In the present
investigation we performed adipose tissue gene expression
studies on a larger scale with no a priori hypothesis using
DNA microarray technology in this human model of ex-
treme obesity. This led to the unexpected finding of serum
amyloid A (SAA) overexpression in subcutaneous white
adipose tissue (sWAT) in both patients, concurrent with
clinical and biological features of systemic amyloidosis.
Based on these findings we performed a series of histo-
pathological, cellular and gene expression studies to assess
for the first time the importance of SAA in common forms
of obesity and to determine whether the increased SAA
expression was specific to extreme obesity due to LEPR
deficiency.
Materials and methods
Clinical investigation protocols The study included sev-
eral groups of subjects. All subjects were premenopausal
Caucasian women. None of the subjects had a familial or
personal history of diabetes, and none were taking medi-
cation. All of the subjects had stable body weights, were at
their maximal peak weight, and were not on a restrictive
diet at entry to the different studies (Table 1). None were
involved in an exercise programme. All clinical investi-
gations were performed according to the Declaration of
Helsinki and were approved by the ethical committees of
the Hôtel-Dieu Hospital (Paris, France), Toulouse Uni-
versity Hospitals (Toulouse, France), the Third Faculty of
Medicine (Charles University, Prague, Czech Republic)
and Maastricht University (Maastricht, The Netherlands).
Informed consent was obtained from all patients.
In the first set of experiments, the transcriptional profiles
of sWAT samples from the two LEPR-mutated women
(Patient 1 and Patient 2) were compared with those of
sWAT samples from a group of healthy obese women
(denoted as ‘reference pool’) who had circulating leptin
levels consistent with their corpulence (range 44–98 ng/ml)
(‘Gene profiling’ column in Table 1). This group of mor-
bidly obese women were followed by the Department of
Nutrition of the Hôtel-Dieu Hospital. The clinical charac-
teristics of the LEPR-mutated subjects have been described
previously [18, 19]. For Patient 1, sWAT abdominal biop-
sies were performed and metabolic parameters were de-
termined in 1997 and 2000, when the patient was 19 and 22
years old, respectively. Samples of sWAT were collected
from Patient 2 during an abdominal lipectomy performed
in 2001, when the patient was 17 years old, justified by the
mechanical consequences of extreme adiposity.
In the second set of experiments we investigated the
regulation of SAA in weight-stable commonly obese pa-
tients and in non-obese subjects (‘Obese and control sub-
jects’ column in Table 1), as well as during a nutritional
challenge in obese women (‘Response to a very-low-
calorie diet’ column in Table 1). The group of 34 healthy
obese patients were prospectively recruited by the Depart-
ment of Nutrition at the Hôtel-Dieu Hospital. Patients in
this group were different to the obese women constituting
the reference pool mentioned above. The 27 lean subjects
(control subjects) were volunteers recruited by the Obesity
Research Unit at Toulouse Hospital and the Department of
Nutrition at the Hôtel-Dieu Hospital. Biopsy specimens of
sWATwere obtained from a subset of nine control subjects
(‘Control subjects, basal’ column in Table 1).
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In order to assess the changes in the expression of the
gene encoding SAA and circulating levels of the protein
after caloric restriction, a group of 21 obese volunteers
received a very-low-calorie diet (3.35 kJ/day) for 28 days
at the Department of Sports Medicine and Obesity Unit at
Charles University. Biopsy specimens of sWAT were ob-
tained at Day 1 and Day 28 in a subset of ten patients
(‘Response to a very-low-calorie diet’ column in Table 1).
The third set of experiments aimed to analyse the ef-
fects of a leptin injection on inflammatory markers and
SAA expression. Six healthy male volunteers (mean age
25±5 years, mean BMI 24±1.7 kg/m2) recruited at the
Department of Human Biology at Maastricht University
(Maastricht, The Netherlands) received an injection of 60
mg of pegylated recombinant leptin (PEG-leptin) for 3
days. Blood and sWAT samples were obtained before and
after leptin treatment (when plasma leptin concentrations
were at their peak).
In the three sets of experiments, sWAT samples were
obtained by needle biopsy from the peri-umbilical area
under local anaesthesia (1% xylocaine) after an overnight
fast. The same standard operating procedures were fol-
lowed at the different participating centres for all groups
studied. Biopsy specimens of sWAT were washed with
sterile 0.9% sodium chloride solution, immediately frozen
in liquid nitrogen and stored at −80°C until analysis.
Gene expression profiling Total RNA was prepared using
the RNeasy total RNA Mini Kit (Qiagen, Courtaboeuf,
France). The RNA concentration and integrity of all indi-
vidual samples were assessed using the Agilent 2100
Bioanalyzer (Agilent Technologies, Massy, France). Ali-
quots (15 μg) of total RNA from each of the 14 obese
women (see Table 1 for clinical data) without a LEPR
mutation were pooled to provide a reference for micro-
array experiments. The MessageAmp RNA Kit (Ambion,
Austin, TX, USA) was used to amplify mRNA [20, 21].
The CyScribe First-Strand cDNA Labelling Kit (Amers-
ham Biosciences, Orsay, France) was used to label 15 μg
of amplified RNA. The amplified RNA from the pool of
obese women was labelled with Cy3, whereas the am-
plified RNA from the two patients with a LEPR mutation
was labelled with Cy5. A duplicate of each sample of
amplified RNA from the LEPR-mutated patients was hy-
bridised against the amplified RNA from the pool (i.e. four
hybridisations). The labelled cDNA mixtures were hy-
bridised according to the protocol described at http://
cmgm.stanford.edu/pbrown/protocols/index (accessed 8
March 2004). The cDNA microarrays consisted of PCR-
amplified cDNAs printed on glass slides with 42,786 spots
representing 29,308 UniGene clusters. The procedure has
previously been described in detail [20, 21]. Briefly, after
scanning the four arrays, the resulting images were ana-
lysed using Stanford Microarray Database Online resources
(http://genome-www5.stanford.edu/MicroArray/SMD, ac-
cessed 8 March 2004). A uniform scale factor was applied
to normalised signal intensities between Cy5 and Cy3, and
then the data were filtered. Using an average intensity 2.5
times above the background, 21,471 cDNA ratios were
recovered for all four experiments. After normalisation in
log-space to set the mean to 0 and the standard deviation to
1, the data were analysed using the significance analysis of
microarray (SAM) procedure (http://www-stat.stanford.
edu/~tibs/SAM, accessed 8 March 2004). This method
provides a list of significant genes and an estimate of the
false discovery rate (FDR), which represents the percentage
of genes that could have been identified by chance [22].
Quantitation of mRNA levels Quantitative RT-PCR was
performed using the GeneAmp 7000 Sequence Detection
System (Applied Biosystems, Courtaboeuf, France) as
previously described [20]. We used 18S rRNA as the con-
trol. Because of the very high degree of homology between
SAA1 and SAA2, the primer pairs designed for SAA1
mRNA also detected SAA2 mRNA. Measurements of
SAA2 and SAA4 mRNA levels were specific.
Studies on adipocytes and cell types of the stroma vascular
fraction Samples of sWATwere obtained from nine female
subjects undergoing abdominal lipectomy in accordance
with French laws on biomedical research. The specimens of
subcutaneous fat were digested using collagenase (type 1;
Biochrom, Berlin, Germany) as described previously [23].
Mature adipocytes and the stroma vascular fraction (SVF)
Table 1 Clinical characteristics of obese subjects and control subjects
Gene profiling Obese and control subjects Response to a very-low-calorie diet
Patient 1
(n=1)
Patient 2
(n=1)
Reference pool
(n=14)
Control
subjects
(n=27)
Obese
subjects
(n=34)
Control
subjects,
basal (n=9)
Obese subjects
before diet
(n=21)
Obese subjects
after diet
(n=21)
Sex (ratio of
women/men)
1:0 1:0 14:0 21:6 29:5 9:0 21:0
Age (year) 22 17 38±2 [24–47] 35.5±.5 39.5±1.8 32±3.2 37±1.2
Weight (kg) 180 207 146.5±7 [116–189] 65.8±5 109±4.5a 62±2.0 95±0.3a 89±2.5b
BMI (kg/m2) 74 85 51.5±2 [43–65] 23.5±0.5 38.1±1.4a 22.5±2.0 34.0±0.7a 31.0±0.8b
Data are presented as means±SEM [ranges]
ap<0.001 vs baseline values of non-obese subjects
bp<0.001 vs baseline values in obese subjects (non-parametric Wilcoxon signed-rank test)
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were separated by centrifugation, lysed with denaturing
buffer from the RNeasy total RNA Mini Kit (Qiagen), and
then stored at −80°C prior to mRNA preparation.
Histological, immunohistochemical and ultrastructural
analysis of adipose tissue All samples were fixed in 4%
paraformaldehyde, dehydrated, paraffin embedded and sec-
tioned (thin sections of 5 μm). Biopsy specimens obtained
from the kidney, antrum and duodenum of Patient 1 and
sWAT samples from Patient 2 were processed for haema-
toxylin–eosin staining, for Congo-red staining (examined
using light and polarised microscopy), and for immunohis-
tochemical analysis of SAA protein as described below.
Since morphological analyses cannot be performed on
samples collected by needle biopsies, sWAT samples from
seven morbidly obese patients (mean BMI 47.55±5 kg/m2),
five obese patients (mean BMI 33.1±3.3 kg/m2) and two
non-obese subjects (BMI 20 and 21 kg/m2) were obtained
during plastic surgery performed at the Hôtel-Dieu Hos-
pital. These subjects were different to the nine obese sub-
jects described in the section ‘Studies on adipocytes and
cell types of the stroma vascular fraction’. All samples of
adipose tissue, skeletal muscle and gut (used as negative
control), and a ganglia biopsy (positive control) from a
deceased patient with amyloidosis as the cause of death,
were stained with haematoxylin–eosin or processed for
immunohistochemical detection of SAA proteins with an
anti-SAA antibody (Dako, Trappes, France) according to a
standard immunoperoxidase procedure. Adipose tissue ex-
plants (300 mg) from one morbidly subject (BMI 49 kg/
m2) and two obese subjects (BMI 30.9 and 31 kg/m2) were
incubated in 3 ml of DMEM containing 1% BSA, peni-
cillin (100 U/ml), streptomycin (100 mg/ml) and Protease
Inhibitor Cocktail (Roche Diagnostics, Germany) for 24.
Following incubation, supernatants were collected and
SAA secretion was measured using the ELISA Cytoscreen
Immunoassay Kit (BioSource International, Camarilla,
CA, USA).
Ultrastructural analysis (by transmission electron mi-
croscopy) of sWAT was also performed for Patient 2 and
for 16 obese premenopausal female patients (mean BMI
43.5±7.5 kg/m2) from the Institute of Normal Human
Morphology–Anatomy at the University of Ancona (Italy).
Small fragments of sWATwere processed for transmission
electron microscopy as described previously [24]. Electron
microscopy was performed on several sections (at least
four sections) of random samples of the tissue. Compar-
ison of light microscopy sections with resin-embedded
sections ensured that representative areas were studied.
Biochemical analysis Concentrations of SAA were mea-
sured using the ELISA Cytoscreen Immunoassay Kit (Bio-
Source International) [25]. Serum leptin concentrations
were determined using a standard kit (Linco Research, St.
Charles, MO, USA). Levels of IL-6 were evaluated using
ELISA (Quantikine HS600B; R&D Systems Europe,
Abingdon, UK). Plasma C-reactive protein was measured
by an immunoturbidity method using an Olympus AU600
automated analyser (reference OS6147; Olympus Optical,
Tokyo, Japan).
Statistical analysis Data are expressed as means±SEM.
Statistical analysis was performed using JMP statistical
software (SAS Institute, Cary, NC, USA). Comparisons
between mRNA levels before and after caloric restriction,
before and after leptin administration, and between SAA
plasma levels before and after caloric restriction were
made using a non-parametric test (Wilcoxon signed-rank
test). Plasma SAA concentrations in obese and non-obese
groups were compared using the Mann–Whitney rank test.
The significance of correlations between the levels of SAA
circulating levels and clinical parameters was calculated
using the non-parametric Spearman’s rank correlation test.
A p value of less than 0.05 was considered statistically
significant.
Results
Overexpression of SAA in LEPR-deficient women The
sWAT transcriptional profiles of the two patients with
extreme obesity due to LEPR mutation were compared
with those of 14 morbidly obese women (see Table 1 for
clinical data). The SAM statistical procedure was used to
control for multiple testing [22]. Of 21,471 cDNAs with
signals recovered in all experiments and an estimated FDR
of <1.2%, SAM isolated 645 cDNAs, among which 349
were overexpressed (mean fold change 1.8, range 1.5–3.5)
and 296 were underexpressed (mean fold change 1.6,
range 1.3–4.5) in the two LEPR-mutated patients. Fifty-
four percent of the differentially expressed genes were
expressed sequence tags (ESTs) or hypothetical proteins.
Genes encoding immune and inflammatory response pro-
teins were among the main categories represented; 10%
of the differentially expressed genes were members of this
category (see Table 1 of the electronic supplementary ma-
terial). Four transcripts of plasma acute-phase proteins
(SAA1, SAA2, SAA4 and haptoglobin) were overex-
pressed (fold change range 2.1–3.5), and SAAswere among
the most highly overexpressed transcripts. The changes in
concentrations of SAA1, SAA2 and SAA4 mRNAs were
assessed using quantitative RT-PCR. The results confirmed
the microarray data for SAA2 (fold change 1.3 and 1.7) and
SAA4 (fold change 1.5 and 1.9) in Patient 1 and Patient 2,
respectively. Combined detection of SAA1 and SAA2
mRNA showed that levels were increased (fold change 1.3)
in Patient 2.
Overexpression of SAA in sWAT and systemic amyloidosis
Samples of sWAT were obtained from Patient 1 (LEPR-
mutated subject) in 1997 and in 2000. Over this period of
time the clinical condition of the patient deteriorated. In
1997, Patient 1 had proteinuria levels of <1 g/24 h; how-
ever, she rapidly developed a nephrotic syndrome in 2000,
and developed renal insufficiency leading to dialysis 1 year
later. An examination of the kidney biopsy under light
(Fig. 1a), by polarised microscopy (data not shown), and
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by immunohistochemistry (Fig. 1b) using specific anti-
SAA antibodies led unambiguously to the diagnosis of
kidney AA amyloidosis. Amyloid A deposits were found in
the duodenum and antrum (Fig. 1c, d). Exhaustive clinical,
biological and radiological investigations did not detect
any common cause of secondary amyloidosis (infection,
neoplasia, inflammatory disease such as arthritis) at the
time of diagnosis or during the 9 years of follow-up. The
patient did not experience recurrent attacks of fever, pain
or skin lesions, or any other symptoms indicative of he-
reditary periodic fever [26]. We found no evidence of
mutations associated with hereditary periodic syndromes
[27, 28].
Since the mRNAs of all SAA isoforms were over-
expressed in Patient 2, the younger patient, relative to the
reference pool of morbidly obese women, we performed a
morphological analysis of sWAT in order to determine
whether any early features of amyloidosis and/or inflam-
mation were present. Immunohistochemical investigations
revealed the presence of SAA proteins within well-dif-
ferentiated adipocyte cytoplasm (Fig. 2). Morphological
features of inflammation were demonstrated on histolog-
ical examination. Approximately 40% of the small arte-
rioles had been infiltrated by lymphocytes, and most of
them had thickened walls (data not shown). Electron mi-
croscopy revealed features unique to this patient compared
with the 16 morbidly obese control subjects. Vascular walls
and all intercellular spaces, including the narrow intercel-
lular space between adipocytes, had been infiltrated by
collagen fibrils (Fig. 3a), and activated fibroblasts were
identified (Fig. 3b). A clear increase in collagen arranged
in thick strands surrounding areas of variable size com-
Fig. 1 Amyloid deposits in
kidney and intestinal biopsies of
Patient 1. a Congo-red-stained
renal glomerulus examined by
light microscopy (×20). b De-
posits show immunoreactivity to
anti-SAA antibodies (×10).
c Congo-red-stained fragments
of duodenum show large vas-
cular SAA deposits (×20).
d Congo-red-stained antrum
biopsy shows vascular deposits
(×20)
Fig. 2 Amyloid protein in adi-
pocytes of Patient 2. a The
cytoplasm of mature adipocytes
shows immunoreactivity to anti-
SAA antibodies (×40). b Adi-
pocytes are immunoreactive in
the perinuclear area (×100)
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posed of unilocular small adipocytes was also observed
(Fig. 3c–e). In the absence of any alteration in renal func-
tion in Patient 2, no renal biopsy has been performed for
this subject as yet.
In order to document the low-grade inflammatory status
of the two LEPR-mutated subjects, we measured plasma
circulating levels of SAA on several occasions and eval-
uated other inflammation-related parameters. Plasma SAA
concentrations were moderately increased in Patient 2
(range 12–30 μg/ml) and Patient 1 (range 10–60 μg/ml)
compared with those in non-obese subjects (4.9±2.3 μg/
ml, range 0.8–16.6 μg/ml), and were within the upper
range of those in subjects with common obesity (Fig. 4a).
Circulating levels of IL6 were also increased in the LEPR-
mutated patients (5.7 and 6 pg/ml) compared with those in
control subjects (2.1±1.5 pg/ml) and obese subjects (2.8±
0.2 pg/ml) (‘Obese and control subjects’ in Table 1).
Levels of C-reactive protein were also increased in Patient
2 (range 16–22 mg/l) relative to those in non-obese sub-
jects (1.3±0.2 mg/l) and obese subjects (5±2.5 mg/l).
Expression of SAA in mature adipose cells of obese
subjectsWewished to determine whether the SAA detected
in adipose tissue was produced by adipocytes or by the cells
of the SVF, which include preadipocytes, endothelial cells
andmonocytes/macrophages.We first investigated the pres-
ence and relative mRNA levels of all SAA isoforms. The
expression of all SAA isoform mRNAs was higher in ma-
ture adipocytes than in SVF cells. The ratio of adipocyte/
SVF concentrations was 49±24 (range 10–192) for SAA1+
Fig. 3 Electron microscopy
morphological analysis of sWAT
of Patient 2. a Adipose tissue
structure with three adipocytes
indicated by an asterisk
(×1,000). b Higher magnifica-
tion of the black square shown
in a (×4,900). The f indicates an
activated fibroblast that pro-
duces collagen fibrils. c Nu-
merous collagen fibrils are
present and infiltrate the inter-
stitial space between adipocytes
(×2,570). d Higher magnifica-
tion of the black square shown
in c (×14,000). e Higher mag-
nification of the black square
shown in d (×35,000). The
arrow indicates a collagen fibril
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Fig. 4 Circulating levels of
SAA and SAA mRNA expres-
sion in sWAT of control subjects
(open bars), obese subjects from
the ‘Obese and control subjects’
group in Table 1 (grey bar),
obese subjects from the ‘Re-
sponse to a very-low-calorie
diet’ group in Table 1 before the
diet (black bars) and after the diet
(striped bars). The data are
means±SEM. a Concentration of
SAA in 34 obese subjects, in 27
non-obese subjects, and in 21
obese patients before and after a
very-low-calorie diet. *p<0·01;
***p<0.0002. b Expression of
transcripts for the SAA isoforms
(SAA1+2, SAA2, SAA4) in
sWAT of nine control subjects
and 10 obese women before and
after a very-low-calorie diet.
**p<0.001; NS=0.1
524
SAA2, 70±35 (range 10–275) for SAA2, and 22±7 (range
5–62) for SAA4 (p<0.01). The results of the gene expres-
sion analysis were confirmed by immunohistochemical de-
tection of SAA in sections of sWAT. Strong positive staining
was observed in the perinuclear area where the cytoplasm
is richer in Golgi complexes and endoplasmic reticulum
(Figs. 2, 5). In contrast, all the other cell types (fibroblasts,
endothelial cells, smooth muscle cells of the vessel walls)
tested negative, clearly indicating that the SAA protein de-
tected in adipose tissue was derived from fully mature
adipocytes.
Expression of SAA in common forms of obesity and
variation with nutritional status We further investigated
whether adipose cell SAA overproduction was a feature
specific to morbid obesity caused by LEPR mutation or
was more generally related to the excess fat mass seen in
common obesity. Expression of SAA in nine non-obese
individuals was compared with that in ten weight-stable
obese subjects before caloric restriction (‘Response to a
very-low-calorie diet’ subjects in Table 1). As shown in
Fig. 4b, the average levels of the transcripts for the SAA
isoforms were statistically different between the obese and
non-obese subjects. In all subjects, significant correlations
were found between the mRNA levels of the three dif-
ferent SAA isoforms (r=0.9, p<0.001 for SAA1 vs SAA2;
r=0.84, p<0.001 for SAA2 vs SAA4; and r=0.89, p<0.001
for SAA1 vs SAA4). Immunohistochemical analysis of
sWAT samples obtained from obese and non-obese sub-
jects showed that, in non-obese subjects, <5% of the adi-
pose cells were immunoreactive for SAA, whereas the
corresponding frequency in obese subjects was >20%
(Table 2). Interestingly, the level of SAA immunoreactiv-
ity observed in morbidly obese subjects was comparable to
that observed in Patient 2 (Table 2). We also detected the
SAA protein in the media in which adipose tissue explants
from three obese subjects undergoing plastic surgery were
incubated. Over a 24-h period, 31.4 ng of SAA were re-
leased per gram of adipose tissue from explants from a
morbidly obese subject (BMI 49 kg/m2). The correspond-
ing figures for two obese subjects, one with a BMI of
30.9 kg/m2, the other with a BMI of 31 kg/m2, were 3.6
and 7.6 ng/g of adipose tissue, respectively.
Over the course of a 4-week very-low-calorie diet that
induced a substantial decrease in body weight (‘Response
to a very-low-calorie diet’ column in Table 1) the ex-
pression of the transcripts for all of the SAA isoforms
Fig. 5 Immunohistochemical detection of SAA protein in sWAT of
obese subjects. Strong positive staining was observed in ganglia (a)
(×20) and sWAT (b) (×40) of an amyloidosis-deceased patient, used
as positive control. Gut (c) (×20) and skeletal muscle (d) (×20) from
a massively obese patient (BMI 57 kg/m2) stained negative. In
sWAT from a non-obese patient (BMI 20 kg/m2) rare, weakly pos-
itive adipocytes were observed (e) (×100), while a stronger pos-
itivity and a high number of positive adipocytes were found in obese
(BMI 33 kg/m2) (f) (×100) and morbidly obese patients (BMI 57
kg/m2) (g) (×20) and (h) (×100). Capillaries are indicated by an
asterisk, nuclei by a small n, and the arrow indicates cytoplasmic
perinuclear positivity
Table 2 Quantification (%) of SAA and adipocytes in obese and
control subjects by immunohistochemistry
BMI (kg/m2) Number of subjects SAA-positive cells (%)
<25 2 <4
30–45 5 14
>45 5 22.5
LEPR-mutated
Patient 2
1 22
All immunohistochemistry-tested patients were grouped according
to BMI and the percentage of positive adipocytes counted
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decreased by 45–75% (Fig. 4b). The data on SAA ex-
pression in sWAT were consistent with the plasma levels
of SAA (Fig. 4a). Circulating levels of SAA were sig-
nificantly higher in the 34 obese patients (16.4±1.7 μg/ml,
range 0.9–67 μg/ml) than in the 27 non-obese subjects
(4.9±2.3 μg/ml, range 0.8–16.6 μg/ml) (Fig. 4a; ‘Obese
and control subjects’ in Table 1). There was a significant
correlation between circulating SAA levels and BMI
(r=0.73, p<10−4). No relationship was observed between
the age of the subject and the level of SAA expression.
There were no differences between non-obese healthy men
and women in terms of the concentration of circulating
SAA levels (p=0.7).
Caloric restriction significantly reduced SAA plasma
levels (Fig. 4a) in the 21 obese subjects who followed the
caloric restriction protocol (‘Response to a very-low-
calorie diet’ subjects in Table 1). In addition, we observed
a significant correlation between the amount of weight loss
and the change in circulating levels of SAA in this group
(r=0.55, p=0.01).
SAA expression after leptin administration We next stud-
ied the influence of the injection of leptin on SAA ex-
pression in sWAT. To avoid the confounding effect of
obesity-induced leptin resistance, leptin was administered
to six healthy subjects at a concentration that would pro-
duce a supraphysiological blood level of leptin. After 3
days of treatment, the mean serum leptin concentration
increased from 3±1 μmol/l to 2112±186 μmol/l (p<0.016);
however, the expression of SAA1+2, SAA2 and SAA4 did
not change significantly (ratio of after/before leptin 0.83±
0.1, 0.93±0.3 and 0.93±0.15, respectively, p>0.05). The
measurements of circulating levels of SAA also showed
no significant change (p=0.13).
Discussion
The presence of AA amyloidosis together with SAA over-
expression in the sWATof a subject with extreme adiposity
due to a LEPR mutation prompted a series of investiga-
tions, the results of which indicate that SAA is expressed
by adipocytes and is regulated by nutritional changes. This
suggests that SAA could contribute to the systemic com-
plications of obesity in humans. The SAA proteins are a
family of apolipoproteins that were, until now, thought to
be mainly expressed in hepatocytes. They may be involved
in cholesterol transport and in the early response to injury.
The SAAs are precursors of amyloid A, a constituent of the
amyloid fibrils that are involved in AA amyloidosis [29,
30]. This form of amyloidosis is a complication that is
associated with many inflammatory conditions (including
rheumatoid arthritis and neoplasia). Amyloid deposits have
also been found in some chronic diseases, such as Alz-
heimer’s disease, dialysis-related amyloidosis and athero-
sclerosis [30]. The causes and effects of amyloid deposition
are uncertain in these pathologies, which are all character-
ised by a low-grade inflammation.
Our data from gene expression and immunohistochem-
ical experiments demonstrate that SAA mRNA and protein
are expressed in human adipocytes. Other cell types found
in adipose tissue do not seem to significantly contribute to
SAA expression. These findings are in agreement with in
vitro and in vivo studies performed in rodents. Mouse
adipose tissue expresses transcripts of the genes encoding
SAA4 and SAA3, which correspond to pseudogenes in
humans [31, 32]. The expression of SAA3 in murine 3T3-
L1 adipocytes has been shown to be strongly induced by
TNF-α and lipopolysaccharides in vitro [31].
In the present study we have demonstrated that the
overproduction of SAA in adipose tissue is not exclusive
to LEPR-mutated subjects as it is also observed in obese
subjects with a functional leptin receptor, particularly in
morbidly obese subjects. In addition, weight loss produced
by calorie restriction in obese subjects is associated with
reductions in levels of SAA mRNA and protein, con-
firming that SAA concentrations are highly regulated by
the nutritional status of the individual. Thus, the overex-
pression of SAA in LEPR-mutated subjects is due to ex-
treme early onset adiposity as opposed to the absence of
leptin signalling. This was confirmed by the lack of SAA
regulation observed in normal subjects following the ad-
ministration of a supraphysiological dose of leptin. In
accordance with these results, gene expression profiling in
the adipose tissue of ob/ob mice showed that SAA over-
expression was only partially corrected by leptin [32].
The relative contributions made by adipose tissue and
the liver to the increase in circulating levels of SAA are not
known. Using immunohistochemistry we showed that, in
mature adipocytes, SAA protein is localised in cytoplasmic
regions that are very rich in rough endoplasmic reticulum/
Golgi apparatus (the cytoplasmic organelles involved in the
synthesis of secreted proteins). Electron microscopy did
not reveal any amyloid deposits in the intercellular spaces
in sWAT samples from the LEPR-mutated patients. This
suggests that, even if SAA is synthesised in adipose tissue,
it could be delivered to the systemic circulation together
with SAA from other tissues, particularly the liver. Finally,
our preliminary observations in three obese subjects re-
vealed that SAA protein is released into the media in which
adipose tissue explants are incubated. Together, these ob-
servations provide further evidence that adipose tissue
contributes to the increased circulating SAA levels ob-
served in morbidly obese subjects.
The biological function of SAA, particularly its role in
glucose and lipid metabolism, has yet to be fully es-
tablished. When associated with HDL particles, SAA pro-
tein may impair reverse cholesterol transport, and it has
been implicated in the decreased HDL levels observed
during inflammation [33]. Transgenic mice overexpressing
SAA have been shown to have similar lipoprotein profiles
to wild-type mice [34]. In humans, circulating SAA levels
were found to be correlated with atherogenic remnant-like
lipoprotein particles in type 2 diabetic patients with coro-
nary heart disease [35], and with HbA1c but not with HDL
cholesterol in diabetic subjects [36]. The Tanis protein has
recently been described as a putative receptor for SAA,
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and has been demonstrated to be deregulated in diabetic
obese rats [37]. It has been shown that the expression of
skeletal muscle and adipose tissue Tanis/SelS mRNA is
positively correlated with circulating levels of SAA in
humans, and that it is induced by insulin infusion in adi-
pose tissue from type 2 diabetic subjects. These data sug-
gest that SAA protein and its putative receptor could be
involved in insulin signalling processes [38]. Our micro-
array data did not provide any evidence for Tanis/SelS
regulation in the two LEPR-mutated patients. However,
preliminary analysis in subjects with common obesity
indicates trends towards correlations between the expres-
sion of SAA and fasting insulin status and HDL choles-
terol levels (data not shown). These results need to be
confirmed and extended to a larger cohort.
The link between the increase of SAA in the context of
morbid obesity and the presence of AA amyloidosis in
LEPR-mutated subjects is questionable. Although an early
study on ob/ob mice reported the occurrence of amyloido-
sis in a model of massive obesity [39], our observations
in LEPR-mutated patients appear to contradict previous
findings linking AA amyloidosis to chronically high cir-
culating concentrations of SAA [40]. Repetitive measure-
ments of circulating SAA showed that this protein never
reached extremely high levels in Patient 1. This finding is
contrast to the peak acute-phase response and the markedly
elevated levels of SAA (>1000 mg/l) associated with
chronic inflammatory disease. No symptoms indicative of
hereditary periodic fever [26, 27] were observed during 9
years of regular exhaustive clinical and biological check-
ups. At the present time classic inflammation sources of
AA amyloidosis can be ruled out. Whether extreme obesity
could have contributed to the pathogenesis of AA amyloid-
osis by creating a low-grade inflammation through the
exacerbated production of proinflammatory molecules by
adipose and liver tissues remains to be determined.
While increased concentrations of circulating SAA are
considered to be a prerequisite for AA amyloidosis, sev-
eral other mechanisms could be important. Enlargement of
fat mass around organs could contribute to a local effect of
SAA, as could dysfunction of SAA proteolytic processes
and remodelling of the extracellular matrix [30, 41, 42].
Histopathological analysis of sWAT samples from Patient
2 revealed signs of inflammation, including fibroblast ac-
tivation and infiltration by monocyte/macrophage cells
(data not shown), as well extracellular matrix components
with an unusual morphology.
Increased SAA mRNA and protein expression in adi-
pocytes and the liver are associated with increased cir-
culating levels of SAA and the increased expression of
associated proteins in subjects with common obesity. This
suggests that amyloid deposition may be a potential com-
plication of morbid obesity. Secondary amyloidosis leads
to proteinuria and microalbuminuria [43], which are uri-
nary features seen in morbid obesity [44, 45]. Histological
studies are scarce, particularly in morbid obesity where
kidney biopsy is technically difficult. Hence, the presence
of amyloidosis has not been systematically investigated.
In conclusion, our work reveals that adipocytes are able
to express SAA mRNA and protein. In the present paper
we have described a previously unsuspected link between
extreme obesity and systemic AA amyloidosis associated
with kidney dysfunction. These data suggest that the over-
production of the SAA family of proteins in human adipose
tissue may contribute to morbidity in obese individuals. A
systematic search for amyloidosis should be carried out
on sWAT biopsies when kidney dysfunction secondary to
obesity is suspected.
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